Aveanna Healthcare (NASDAQ:AVAH) Cut to "Buy" at Wall Street Zen

Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a note issued to investors on Friday.

A number of other brokerages have also commented on AVAH. Truist Financial lowered their price objective on Aveanna Healthcare from $6.00 to $5.50 and set a "hold" rating on the stock in a report on Friday, April 11th. UBS Group increased their price target on Aveanna Healthcare from $4.50 to $5.00 and gave the company a "sell" rating in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $5.13.

Aveanna Healthcare Price Performance

NASDAQ:AVAH traded up $0.20 during trading hours on Friday, reaching $5.02. The company's stock had a trading volume of 1,216,413 shares, compared to its average volume of 339,134. The company has a market cap of $979.35 million, a price-to-earnings ratio of 251.00 and a beta of 2.03. Aveanna Healthcare has a one year low of $2.40 and a one year high of $6.19. The business's 50-day moving average is $5.13 and its 200-day moving average is $4.87.

Insider Transactions at Aveanna Healthcare

In other Aveanna Healthcare news, insider Patrick A. Cunningham sold 18,500 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $4.93, for a total value of $91,205.00. Following the sale, the insider now directly owns 327,869 shares in the company, valued at $1,616,394.17. This trade represents a 5.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Robert M. Williams, Jr. sold 91,061 shares of the business's stock in a transaction dated Thursday, May 8th. The stock was sold at an average price of $5.84, for a total transaction of $531,796.24. Following the transaction, the insider now owns 545,330 shares in the company, valued at approximately $3,184,727.20. The trade was a 14.31% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,120,925 shares of company stock worth $37,869,472. Company insiders own 7.80% of the company's stock.

Institutional Investors Weigh In On Aveanna Healthcare

Several hedge funds have recently made changes to their positions in the stock. Millennium Management LLC lifted its position in Aveanna Healthcare by 105.0% in the fourth quarter. Millennium Management LLC now owns 400,374 shares of the company's stock worth $1,830,000 after purchasing an additional 205,023 shares during the period. Legal & General Group Plc raised its stake in shares of Aveanna Healthcare by 577.0% in the 4th quarter. Legal & General Group Plc now owns 36,409 shares of the company's stock valued at $166,000 after buying an additional 31,031 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Aveanna Healthcare by 11.1% during the 4th quarter. Rhumbline Advisers now owns 72,663 shares of the company's stock worth $332,000 after acquiring an additional 7,257 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Aveanna Healthcare during the 4th quarter valued at about $223,000. Finally, Deutsche Bank AG increased its stake in Aveanna Healthcare by 32.1% in the fourth quarter. Deutsche Bank AG now owns 34,564 shares of the company's stock valued at $158,000 after acquiring an additional 8,396 shares during the period. Institutional investors own 87.96% of the company's stock.

About Aveanna Healthcare

Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.